Page 1

ELEVATION CONCOLOGY Elevation Oncology Reports Third Quarter 2021 Financial Results Global Expansion of the Phase 2 CRESTONE Study into Canada and Australia Case Study of a Patient with Pancreatic Cancer Harboring an NRG1 Fusion and Treated with Seribantumab Under Compassionate Use Highlighted a Confirmed Partial Response and Durable Clinical Benefit Strengthened Management Team with the Promotion of Valerie Malyvanh Jansen , MD , PhD , to Chief Medical Officer -- NEW YORK , November 12 , 2021 Elevation Oncology , Inc. ( Nasdaq : ELEV ) , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers , today announced financial results for the quarter ended September 30 , 2021 . " The third quarter was marked by continued progress on our mission to bring purpose - built medicines to patients with genomically defined cancers , " said Shawn M. Leland , PharmD , RPh , Founder and Chief Executive Officer of Elevation Oncology . " The CRESTONE Study is now open and enrolling patients in the US , Canada , and Australia . Our collaboration with Caris Life Sciences is revealing a series of potential programs targeting genomic fusions . Finally , I am also pleased to welcome Valerie Malyvanh Jansen , MD , PhD , as our first Chief Medical Officer . " " We are encouraged by the durable clinical benefit seen with seribantumab in the case study of a patient with metastatic pancreatic cancer harboring an NRG1 fusion that was presented at the Australasian Gastro - intestinal Cancer Trials Group conference , ” said Dr. Jansen . “ Separately , we expect to complete enrollment of the first 20 patients in Cohort 1 of CRESTONE in mid - 2022 . We also anticipate presenting initial clinical data at a major medical meeting in mid - 2022 , which will include results from approximately 10 patients from Cohort 1 with meaningful follow - up who have been treated with seribantumab at 3 grams weekly . " Recent Business Highlights Seribantumab Case study of a patient with pancreatic cancer treated with seribantumab under a compassionate use program highlighted a confirmed partial response and durable clinical benefit , representing the first clinical data presented on the use of seribantumab in a patient with a tumor harboring an NRG1 fusion . Treatment with seribantumab was included as part of a case series presentation at the Australasian Gastro - Intestinal Trials Group ( AGITG ) 2021 Annual +1 ( 716 ) 371-1125 | www.elevation oncology.com | 888 7th Ave. , 12th Floor , New York NY , 10106